Jorge Posada, MD
Nephrology · Coral Gables, FLNPI 1225099195
Payments from drug & device makers
Across 1,098 payments — averaging $2288.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$667K
- CSL Behring$428K
- GSK$358K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$276K
- UCB SA$201K
- Boehringer Ingelheim$200K
- plus $383K from 20 others
Across 9 payments — averaging $131.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 638 | $666,872 |
| CSL Behring | 132 | $427,572 |
| GSK | 100 | $358,244 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $275,511 |
| UCB SA | 13 | $201,048 |
| Boehringer Ingelheim | 4 | $200,408 |
| Bayer | 27 | $70,358 |
| Vertex | 1 | $63,610 |
| Alnylam Pharmaceuticals Inc. | 19 | $42,741 |
| Merck | 7 | $41,869 |
| Novo Nordisk AS | 102 | $40,481 |
| AbbVie | 16 | $40,472 |
| AstraZeneca | 7 | $32,574 |
| Novartis | 3 | $21,350 |
| Hoffmann-la Roche Limited | 3 | $16,658 |
| Ardelyx, Inc. | 2 | $5,000 |
| Astrazeneca UK Limited | 8 | $3,786 |
| Ironwood Pharmaceuticals, Inc | 1 | $2,136 |
| Mallinckrodt Enterprises LLC | 1 | $1,403 |
| Pfizer | 1 | $258 |
| Amgen | 2 | $65 |
| Boehringer Ingelheim International GmbH | 1 | $39 |
| Integra Lifesciences Corporation | 1 | $35 |
| Vifor Pharma, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
How this compares
$2,512,554 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Coral Gables
- Luis Garcia-MayolCoral Gables$402K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.